Compare Icl Group Ltd (ICL) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Icl Group Ltd vs Zimmer Biomet Holdings Inc — how do they compare? Icl Group Ltd trades at $5.01 (market cap $6.65B), while Zimmer Biomet Holdings Inc trades at $90.03 (market cap $17.36B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 2.6× Icl Group Ltd's market cap, and Icl Group Ltd pays the higher dividend (3.77%). Which is the better fit depends on your goals.
| ICL | ZBH | |
|---|---|---|
Market Cap | $6.65B | $17.36B |
Sector | Basic Materials | Health |
52-Week High | $7.03 | $107.71 |
52-Week Low | $4.80 | $79.58 |
Enterprise Value | $9.22B | $24.40B |
Dividend Yield | 3.77% | 1.07% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Icl Group Ltd
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and innovative agriculture solutions (IAS). These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North & South America, and the Rest of the world.
Read more on ICL →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
